COMMUNIQUÉS West-GlobeNewswire

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn's Disease with Top-Line Results Expected Mid-2018

02/10/2017 - 13:00

RedHill has curtailed the target sample size in the ongoing first Phase III study with RHB-104 for Crohn's disease (MAP US) from 410 to approximately 325 subjects, of which 322 have been enrolled to date, while [...]

Vistin Pharma ASA : Sale of Opioids and CMO business completed

02/10/2017 - 10:28

Oslo, Norway, 2 October 2017 Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma") announced today that the Company has successfully completed the sale of its opioids and tablet manufacturing business ( [...]

GENFIT annonce sa participation au congrès de l'AASLD 2017

02/10/2017 - 08:36

GENFIT annonce sa participation au congrès de l'AASLD 2017 Nouveaux résultats indiquant un potentiel anti-fibrotique substantiel d'une combinaison propriétaire de deux médicaments issus de la pharmacopée Nouvelles [...]

GENFIT announces its participation at the 2017 AASLD Meeting

02/10/2017 - 08:36

GENFIT announces its participation at the 2017 AASLD Meeting New results indicating a substantial anti-fibrotic potential of a proprietary combination of two drugs from the pharmacopoeia Novel approaches for the [...]

Solon Eiendom ASA : Salg i Q3 2017

02/10/2017 - 08:30

Oslo, oktober 2, 2017 - Solon Eiendom solgte 23 boliger med en samlet verdi på 185 millioner kroner i tredje kvartal i år sammenlignet med 38 boliger med en samlet verdi på 230 millioner kroner i tredje kvartal i fjor. [...]

Solon Eiendom ASA : Sales in Q3 2017

02/10/2017 - 08:30

Oslo, October 2, 2017 - Solon Eiendom sold 23 homes with a total sales value of NOK 185 million during the third quarter of 2017 compared to 38 homes with a total sales value of NOK 230 million in the third quarter of [...]

Verona Pharma plc : Total voting rights

02/10/2017 - 08:00

October 2, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), in conformity with DTR 5.6 of the FCA's Disclosure and Transparency Rules, notifies the market that as at 30 September 2017, the [...]

ESPERITE N.V. (ESP) publishes its half-year report. Revenues and results were unexpectedly impacted by pending legal actions.

02/10/2017 - 07:17

CEO , Frédéric Amar will convert 1.5 million shares and will subscribe to 1 million new shares to support the business. Zutphen, The Netherlands - 2 October 2017 Esperite NV (Euronext: ESP, "Esperite" or "the Group") [...]

Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress

02/10/2017 - 07:15

Clareon ® intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations Congress program highlights Alcon's 70-year legacy of innovation including 100 [...]

TiGenix to host Analyst and Investor Event in New York City

02/10/2017 - 07:00

PRESS RELEASE TiGenix to host Analyst and Investor Event in New York City Leuven (BELGIUM) - October 2, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on [...]

TiGenix organisera une réunion d'analystes et d'investisseurs à New York

02/10/2017 - 07:00

COMMUNIQUÉ DE PRESSE TiGenix organisera une réunion d'analystes et d'investisseurs à New York Louvain (BELGIQUE) - 2 octobre 2017, 07h. CET - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société biopharmaceutique de [...]

ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP

02/10/2017 - 07:00

REGULATED INFORMATION - INSIDE INFORMATION Caplacizumab meets primary endpoint and key secondary endpoints Statistically significant reduction in time to platelet count response, with at any given time patients treated [...]

ESPERITE N.V. (ESP) delays publication of 2017 Interim Financial Reporting

29/09/2017 - 21:16

Zutphen, The Netherlands - 29 September 2017 Esperite N.V. (Euronext: ESP, the " Company " or " Esperite ") announces that the Company expects to publish its Interim Financial Reporting on or before 2 October 2017. [...]

Summit Therapeutics plc : Exercise of Share Options

29/09/2017 - 19:20

Summit Therapeutics plc ("Summit" or the "Company") EXERCISE OF SHARE OPTIONS Oxford, UK, 29 September 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing [...]

MEDASYS : Chiffre d'affaires et résultats consolidés du 1er semestre 2017

29/09/2017 - 19:15

Clamart, le 29 septembre 2017 - Medasys, principal éditeur et intégrateur français de logiciels médicaux pour établissements de santé, publics et privés, dans les domaines du dossier patient, de la production de soins [...]

GUERBET : Mise à disposition du Rapport Financier semestriel 2017

29/09/2017 - 18:03

Villepinte, le 29 septembre 2017 - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, annonce ce jour avoir mis à la disposition du public et déposé auprès [...]

Khiron Appoints Former DEA Chief of Pharmaceutical Investigations to Advisory Board

29/09/2017 - 17:27

TORONTO, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Khiron Life Sciences Corp. (" Khiron " or the " Company ") reports the appointment of Mr. Matthew Murphy, the former U.S. Drug Enforcement Administration ("DEA") Chief of [...]

Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US

29/09/2017 - 16:10

Bagsværd, Denmark, 29 September 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Fiasp ® (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment [...]

CHMP endorses Tresiba® label update in the EU - new label reflects significant reduction in the risk of severe hypoglycaemia

29/09/2017 - 15:52

Bagsværd, Denmark, 29 September 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has endorsed an update of the EU label with [...]